Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery

Journal of Controlled Release

Volumn 112, Issue 2, 2006, Pages 280-290

  Heyes, James ^a   Hall, Kim ^a   Tailor, Vicky ^a   Lenz, Richard ^a   MacLachlan, Ian ^a  

^a Protiva Biotherapeutics   (Canada)

Author keywords

Liposome; PEG; SNALP; SPLP; Stability

Indexed keywords

CONTROLLED DRUG DELIVERY; HYDROPHILICITY; LIPIDS; MOLECULAR DYNAMICS; POLYMERS; STABILITY; SYNTHESIS (CHEMICAL);

LIPOSOME; RETENTION EFFECT (EPR); SNALP; SPLP;

POLYETHYLENE GLYCOLS;

1 AMINO METHOXYPOLY(ETHYLENE GLYCOL); 1,2 DIOLEYLOXY N,N DIMETHYL 3 AMINOPROPANE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOCHOLINE; CHOLESTEROL; DNA; LIPOSOME; MACROGOL 2000; MACROGOL DERIVATIVE; METHOXYPOLY(ETHYLENE GLYCOL); METHOXYPOLY(ETHYLENE GLYCOL)MESYLATE; N (1,2 DISTEARYLOXYPROPYL)METHOXYPOLY(ETHYLENE GLYCOL)ACETAMIDE; N [METHOXYPOLY(ETHYLENE GLYCOL)CARBAMYL] 1,2 DIMYRISTYLOXLPROPYL 3 AMINE; N [METHOXYPOLY(ETHYLENE GLYCOL)CARBAMYL] 1,2 DISTEARYLOXLPROPYL 3 AMINE; N [METHOXYPOLY(ETHYLENE GLYCOL)SUCCINIMIDYL] 1,2 DISTEARYLOXLPROPYL 3 AMINE; PHOSPHORYLCHOLINE; PROPYLAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DETERMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SYNTHESIS; ENCAPSULATION; IN VIVO STUDY; INCUBATION TEMPERATURE; MALE; MOLECULAR STABILITY; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; THERMOSTABILITY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA; DRUG STABILITY; GENE EXPRESSION; GENE THERAPY; HALF-LIFE; INJECTIONS, INTRAVENOUS; LIPIDS; LIPOSOMES; LUCIFERASES; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR STRUCTURE; NEUROBLASTOMA; PARTICLE SIZE; POLYETHYLENE GLYCOLS; TRANSFECTION;

EID: 33646152762     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.02.012     Document Type: Article

References (45)

1. MacLachlan I., Cullis P., and Graham R.W. Progress towards a synthetic virus for systemic gene therapy. Curr. Opin. Mol. Ther. 1 (1999) 252-259
2. Fenske D.B., and Cullis P.R. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol. 391 (2005) 7-40
3. Dvorak H.F., Nagy J.A., Dvorak J.T., and Dvorak A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133 (1988) 95-109
4. Webb M.S., Harasym T.O., Masin D., Bally M.B., and Mayer L.D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer 72 (1995) 896-904
5. Northfelt D.W., Martin F.J., Working P., Volberding P.A., Russell J., Newman M., Amantea M.A., and Kaplan L.D. Doxorubicin encapsulated in liposomes containing surface-found polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 36 (1996) 55-63
6. Mayer L.D., Bally M.B., Loughrey H., Masin D., and Cullis P.R. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 50 (1990) 575-579
7. Monck M.A., Mori A., Lee D., Tam P., Wheeler J.J., Cullis P.R., and Scherrer P. Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. J. Drug Target. 7 (2000) 439-452
8. Tam P., Monck M., Lee D., Ludkovski O., Leng E., Clow K., Stark H., Scherrer P., Graham R.W., and Cullis P.R. Stabilized plasmid lipid particles for systemic gene therapy. Gene Ther. 7 (2000) 1867-1874
9. Ambegia E., Ansell S., Cullis P., Heyes J., Palmer L., and MacLachlan I. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim. Biophys. Acta 1669 (2005) 155-163
10. Semple S.C., Klimuk S.K., Harasym T.O., Dos Santos N., Ansell S.M., Wong K.F., Maurer N., Stark H., Cullis P.R., Hope M.J., and Scherrer P. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta-Biomembr. 1510 (2001) 152-166
11. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V., Vaish N., Zinnen S., Vargeese C., Bowman K., Shaffer C., Jeffs L.B., Judge A.D., MacLachlan I., and Polisky B.A. Potent and persistent in vivo anti-HBV activity of chemically modified siRNA's. Nat. Biotechnol. 23 (2005) 1002-1007
12. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., and Danielsen M. Lipofection - a highly efficient, lipid-mediated DNA transfection procedure. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 7413-7417
13. Semple S., Chonn A., and Cullis P. Interactions of liposomes and lipid-based carriers with blood proteins: relation to clearance behavior in vivo. Adv. Drug Deliv. Rev. 32 (1998) 3-17
14. Stamatatos L., Leventis R., Zuckermann M.J., and Silvius J.R. Interactions of cationic lipid vesicles with negatively charged phospholipid vesicles and biological membranes. Biochemistry 27 (1988) 3917-3925
15. Litzinger D.C., Brown J.F., Wala I., Kaufman S., Van G., Farrell C., and Collins D. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta 1281 (1996) 139-149
16. Woodle M.C. Poly(ethylene glycol)-grafted liposome therapeutics. ACS Symp. Ser. 680 (1997) 60-81
17. Oku N., and Namba Y. Long-circulating liposomes. Crit. Rev. Ther. Drug Carr. Syst. 11 (1994) 231-270
18. Woodle M.C., Engbers C.M., and Zalipsky S. New amphipatic polymer lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug. Chem. 5 (1994) 493-496
19. Metselaar J.M., Bruin P., de Boer L.W.T., de Vringer T., Snel C., Oussoren C., Wauben M.H.M., Crommelin D.J.A., Storm G., and Hennink W.E. A novel family of l-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug. Chem. 14 (2003) 1156-1164
20. Mishra S., Webster P., and Davis M.E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 83 (2004) 97-111
21. Webb M.S., Saxon D., Wong F.M.P., Lim H.J., Wang Z., Bally M.B., Choi L.S.L., Cullis P.R., and Mayer L.D. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim. Biophys. Acta 1372 (1998) 272-282
22. Allen T.M., Hansen C., Martin F., Redemann C., and Yauyoung A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066 (1991) 29-36
23. Rejman J., Wagenaar A., Engberts J., and Hoekstra D. Characterization and transfection properties of lipoplexes stabilized with novel exchangeable polyethylene glycol-lipid conjugates. Biochim. Biophys. Acta 1660 (2004) 41-52
24. Karathanasis E., Ayyagari A.L., Bhavane R., Bellamkonda R.V., and Annapragada A.V. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. J. Control. Release 103 (2005) 159-175
25. Zalipsky S., Qazen M., Walker J.A., Mullah N., Quinn Y.P., and Huang S.K. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacylphosphatidylethanolamine. Bioconjug. Chem. 10 (1999) 703-707
26. Shin J., Shum P., and Thompson D.H. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J. Control. Release 91 (2003) 187-200
27. Guo X., MacKay J.A., and Szoka F.C. Mechanism of pH-triggered collapse of phosphatidylethanolamine liposomes stabilized by an ortho ester polyethyleneglycol lipid. Biophys. J. 84 (2003) 1784-1795
28. Choi J.S., MacKay J.A., and Szoka F.C. Low-pH-sensitive PEG-stabilized plasmid-lipid nanoparticles: preparation and characterization. Bioconjug. Chem. 14 (2003) 420-429
29. Masson C., Garinot M., Mignet N., Wetzer B., Mailhe P., Scherman D., and Bessodes M. pH-sensitive PEG lipids containing orthoester linkers: new potential tools for nonviral gene delivery. J. Control. Release 99 (2004) 423-434
30. Semple S.C., Harasym T.O., Clow K.A., Ansell S.M., Klimuk S.K., and Hope M.J. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J. Pharmacol. Exp. Ther. 312 (2005) 1020-1026
31. Judge A.D., McClintock K., Shaw J.R., and MacLachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to pegylated liposomes. Mol. Ther. 13 (2006) 328-337
32. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
33. Monteith D.K., Henry S.P., Howard R.B., Flournoy S., Levin A.A., Bennett C.F., and Crooke S.T. Immune stimulation - a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anti-Cancer Drug Des. 12 (1997) 421-432
34. Judge A., Sood V., Shaw J., Fang D., McClintock K., and MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23 (2005) 457-462
35. Heyes J., Palmer L., Bremner K., and MacLachlan I. Degree of cationic lipid saturation influences fusogenicity and subsequent potency of stable plasmid lipid particles. J. Control. Release 107 (2005) 276-287
36. Wheeler J.J., Palmer L., Ossanlou M., MacLachlan I., Graham R.W., Zhang Y.P., Hope M.J., Scherrer P., and Cullis P.R. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 6 (1999) 271-281
37. Jeffs L., Palmer L., Ambegia E., Giesbrecht C., Ewanick S., and MacLachlan I. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm. Res. 22 (2005) 362-372
38. Heyes J.A., Niculescu-Duvaz D., Cooper R.G., and Springer C.J. Synthesis of novel cationic lipids: effect of structural modification on the efficiency of gene transfer. J. Med. Chem. 45 (2002) 99-114
39. Aronov O., Horowitz A.T., Gabizon A., and Gibson D. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug. Chem. 14 (2003) 563-574
40. Fenske D.B., MacLachlan I., and Cullis P.R. Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol. 346 (2002) 36-71
41. Grit M., Underberg W.J.M., and Crommelin D.J.A. Hydrolysis of saturated soybean phosphatidylcholine in aqueous liposome dispersions. J. Pharm. Sci. 82 (1993) 362-366
42. Vernooij E.A.A.M., Kettenes-van den Bosch J.J., Underberg W.J.M., and Crommelin D.J.A. Chemical hydrolysis of DOTAP and DOPE in a liposomal environment. J. Control. Release 79 (2002) 299-303
43. Woodle M.C., Collins L.R., Sponsler E., Kossovsky N., Papahadjopoulos D., and Martin F.J. Sterically stabilized liposomes - reduction in electrophoretic mobility but not electrostatic surface potential. Biophys. J. 61 (1992) 902-910
44. Chonn A., Semple S.C., and Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo. J. Biol. Chem. 267 (1992) 18759-18765
45. Mortimer I., Tam P., MacLachlan I., Graham R.W., Saravolac E.G., and Joshi P.B. Cationic lipid-mediated transfection of cells in culture requires mitotic activity. Gene Ther. 6 (1999) 403-411